Details of the Drug Reposition

General Information of This Drug (ID: DMRSNEU)

Drug Name
Masitinib   DMRSNEU
Synonyms
Masitinib; 790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
6 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Gastrointestinal stromal tumour DIS6TJYS 2B5B Phase 3 [1]
Pancreatic cancer DISJC981 2C10 Phase 3 [1]
Ovarian cancer DISZJHAP 2C73 Phase 3 [1]
Metastatic gastric or gastroesophageal junction cancer DISNHCB8 2D8Y Phase 3 [2]
Multiple sclerosis DISB2WZI 8A40 Phase 3 [3]
Amyotrophic lateral sclerosis DISF7HVM 8B60.0 Phase 3 [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Indications(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)